Related Experiment Videos
Modulation of integrin-binding selectivity by mutation within the RGD-loop of snake venom proteins: a novel drug
X Lu1, D Lu, M F Scully
1Thrombosis Research Institute, Manresa Road, London, SW3 6LR UK. xlu@tri-london.ac.uk
Current Medicinal Chemistry. Cardiovascular and Hematological Agents
|August 24, 2004
Summary
Snake venom proteins containing the RGD motif are potent integrin antagonists, offering higher efficacy than RGD peptides. Their unique structure and flanking amino acids enhance inhibition, paving the way for new drug development.
Area of Science:
- Biochemistry
- Pharmacology
- Molecular Biology
Background:
- Integrins are transmembrane receptors mediating cell adhesion via binding to RGD sequences in proteins.
- Snake venom contains RGD-containing proteins that act as potent integrin antagonists.
- These venom proteins exhibit significantly higher potency (500-2000x) than short RGD peptides.
Purpose of the Study:
- To review the structure and function of snake venom integrin antagonists.
- To compare their inhibitory mechanisms with RGD peptides and proteins.
- To explore the potential of these antagonists in novel drug development.
Main Methods:
- Structural and functional studies of snake venom RGD proteins.
- Comparative analysis of integrin binding inhibition.
- Assessment of amino acid residue influence on RGD motif function.
Main Results:
- Snake venom RGD proteins inhibit beta1 and beta3 integrins with high potency.
- Inhibitory efficacy is linked to the precise positioning of the RGD tripeptide in a flexible loop.
- Amino acid residues near the RGD motif dictate binding specificity and selectivity.
Conclusions:
- Snake venom RGD proteins represent a powerful class of integrin antagonists.
- Their unique structural features offer advantages over simpler RGD peptides.
- Insights gained can guide the development of novel therapeutic agents targeting integrin function.